BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34773164)

  • 1. Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study.
    Hong CM; Shin JY; Kim BI; Song HC; Yoon JK; Won KS; Kim SM; Cho IH; Jeong SY; Lee SW; Lee J
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1661-1670. PubMed ID: 34773164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioactive Iodine Treatment for Children and Young Adults with Thyroid Cancer in South Korea: A Population-based Study.
    Seo GH; Kong KA; Kim BS; Kang SY; Moon BS; Yoon HJ; Kim HO
    J Clin Endocrinol Metab; 2021 Jun; 106(7):e2580-e2588. PubMed ID: 33755732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
    Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
    Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
    Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
    Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
    Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
    Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.
    Hakala TT; Sand JA; Jukkola A; Huhtala HS; Metso S; Kellokumpu-Lehtinen PL
    Int J Clin Oncol; 2016 Apr; 21(2):231-239. PubMed ID: 26410770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation.
    Han YH; Jeong HJ; Sohn MH; Lee SY; Lim ST
    Q J Nucl Med Mol Imaging; 2020 Mar; 64(1):124-130. PubMed ID: 29521481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?
    Cappagli V; Caldarella A; Manneschi G; Piaggi P; Bottici V; Agate L; Molinaro E; Bianchi F; Elisei R
    Int J Cancer; 2020 Nov; 147(10):2838-2846. PubMed ID: 32449158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer.
    Verkooijen RB; Smit JW; Romijn JA; Stokkel MP
    Eur J Endocrinol; 2006 Dec; 155(6):801-6. PubMed ID: 17132748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study.
    Piscopo L; Volpe F; Nappi C; Zampella E; Manganelli M; Matrisciano F; Totaro P; Pace L; Maurea S; Cuocolo A; Klain M
    Curr Oncol; 2022 Dec; 30(1):37-44. PubMed ID: 36661652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
    Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
    Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative remnant
    Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
    Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing radioiodine ablation for differentiated thyroid cancer.
    Yoo D; Ajmal S; Gowda S; Machan J; Monchik J; Mazzaglia P
    World J Surg; 2012 Jun; 36(6):1255-61. PubMed ID: 22430670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics.
    Kim S; Bang JI; Boo D; Kim B; Choi IY; Ko S; Yoo IR; Kim K; Kim J; Joo Y; Ryoo HG; Paeng JC; Park JM; Jang W; Kim B; Chung Y; Yang D; Yoo S; Lee HY
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3547-3556. PubMed ID: 35362796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of thyroid hormone replacement on the risk of second cancer after thyroidectomy: a Korean National Cohort Study.
    Ho J; Han M; Jung I; Jo YS; Lee J
    Sci Rep; 2023 Sep; 13(1):16280. PubMed ID: 37770542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma.
    Özdoğan Ö; Aksu A; Doğan E; Bülbül O; Güray Durak M; Sevinç Aİ; Bayraktar F; İkiz AÖ
    Ann Nucl Med; 2021 Feb; 35(2):223-231. PubMed ID: 33389664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
    Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.